Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

Phase 4

Completed

Conditions: METABOLIC SYNDROME
PRE-HYPERTENSION
HYPERTENSION

First Posted Date: 2005-09-15

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 507

Registration Number: NCT00170937

Locations: 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

Phase 4

Completed

Conditions: Constipation

First Posted Date: 2005-09-15

Last Posted Date: 2016-03-03

Lead Sponsor: Novartis

Target Recruit Count: 52

Registration Number: NCT00171522

Locations: 🇺🇸
Beth Israel Deacon Medical Center, Boston, Massachusetts, United States
🇺🇸
R/D Clinical Research, Inc., Lake Jackson, Texas, United States
🇺🇸
Heartland Clinical Research, Inc, Omaha, Nebraska, United States

and more 11 locations

Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid

Phase 4

Completed

Conditions: Breast Cancer With Metastatic Bone Disease

Interventions: Drug: Zoledronic acid

First Posted Date: 2005-09-15

Last Posted Date: 2023-08-18

Lead Sponsor: Novartis

Target Recruit Count: 116

Registration Number: NCT00172029

Locations: 🇹🇷
Novartis Investigative Site, Trabzon, Turkey

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

Phase 3

Terminated

Conditions: Hypertension

Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2
Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

First Posted Date: 2005-09-15

Last Posted Date: 2023-10-24

Lead Sponsor: Novartis

Target Recruit Count: 11506

Registration Number: NCT00170950

Locations: 🇩🇰
sites in Denmark, Denmark, Denmark
🇫🇮
sites in Finland, Finland, Finland
🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

and more 2 locations

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-19

Lead Sponsor: Novartis

Target Recruit Count: 40

Registration Number: NCT00166725

Locations: 🇮🇹
Orbassano, Orbassano, Italy

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2005-09-12

Last Posted Date: 2023-12-14

Lead Sponsor: Novartis

Target Recruit Count: 55

Registration Number: NCT00154323

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis, Hip

First Posted Date: 2005-09-12

Last Posted Date: 2012-05-21

Lead Sponsor: Novartis

Target Recruit Count: 1200

Registration Number: NCT00154219

Locations: 🇬🇧
Various Sites, Multiple Cities, United Kingdom
🇺🇸
For US Site Information, contact Novartis Pharmaceuticals, East Hanover, New Jersey, United States